Natera, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6323071042
USD
242.06
5.42 (2.29%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Natera, Inc. stock-summary
stock-summary
Natera, Inc.
Pharmaceuticals & Biotechnology
Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).
Company Coordinates stock-summary
Company Details
201 Industrial Rd Ste 410 , SAN CARLOS CA : 94070-2396
stock-summary
Tel: 1 650 24990901 650 2499091
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 113 Schemes (44.1%)

Foreign Institutions

Held by 291 Foreign Institutions (14.53%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Matthew Rabinowitz
Executive Chairman of the Board, Co-Founder
Mr. Steven Chapman
President, Chief Executive Officer, Director
Mr. Jonathan Sheena
Co-Founder, Chief Technology Officer, Director
Mr. Roelof Botha
Lead Independent Director
Mr. Roy Baynes
Independent Director
Dr. Monica Bertagnolli
Independent Director
Dr. Rowan Chapman
Independent Director
Mr. Todd Cozzens
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
547 Million
(Quarterly Results - Jun 2025)
Net Profit:
-101 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 22,974 Million (Mid Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.74

stock-summary
Return on Equity

-20.32%

stock-summary
Price to Book

18.44